Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cilazapril monohydrate
Drug ID BADD_D00465
Description Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.
Indications and Usage Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
Marketing Status approved
ATC Code C09AA08
DrugBank ID DB01340
KEGG ID D07699; D01069
MeSH ID D017315
PubChem ID 56329
TTD Drug ID D04GKO
NDC Product Code Not Available
UNII 19KW7PI29F
Synonyms Cilazapril | Cilazapril Monohydrobromide | Cilazapril, Anhydrous | Cilazapril Anhydrous | Cilazapril Monohydrate | Ro 31-2848 | Ro 31 2848 | Ro 312848 | Ro-31-2848 | Ro312848 | Cilazapril Hydrate | Cilazapril, (S*)-Isomer | Inhibace
Chemical Information
Molecular Formula C22H33N3O6
CAS Registry Number 92077-78-6
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC2CCCN3CCCC(N3C2=O)C(=O)O.O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Urine output increased13.13.03.002--Not Available
Hot flush08.01.03.027; 24.03.01.005; 21.02.02.001--
Cardiac disorder02.11.01.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Acute kidney injury20.01.03.016--
Liver function test increased13.03.04.031--Not Available
The 5th Page    First    Pre   5    Total 5 Pages